SCHEMBL22636714

SCHEMBL22636714

Cc1oncc1-c1ccc(-c2cccc(F)c2)c(N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.41
FYN P06241 2/20 0.41
TDO2 P48775 4/20 0.41
TAAR1 Q96RJ0 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
MAPT P10636 3/20 0.36
ALOX15 P16050 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CHEK2 O96017 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP1 P29466 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430620 1.00 MAPK1 (0.44) MAPK1TP53FYNTDO2TAAR1
SCHEMBL22637149 0.86 TDO2 (0.51) MAPK1TDO2L3MBTL1PDE3BPDE3A
SCHEMBL29430767 0.86 TDO2 (0.51) MAPK1TDO2L3MBTL1PDE3BPDE3A
SCHEMBL22637054 0.81 TDO2 (0.56) TP53TDO2PDE3BPDE3AMAPT
SCHEMBL29430584 0.81 TDO2 (0.56) TP53TDO2PDE3BPDE3AMAPT
SCHEMBL22637035 0.76 BRD4 (0.37) MAPK1TDO2L3MBTL1MAPTBRD4
SCHEMBL31198523 0.76 MAP4K4 (0.53) TDO2L3MBTL1MAPTSMN1; SMN2MEN1
SCHEMBL17532994 0.76 TDO2 (0.66) TP53FYNTDO2TAAR1L3MBTL1
SCHEMBL22648191 0.76 TAAR1 (0.41) MAPK1FYNTDO2TAAR1PDE3B
SCHEMBL22636845 0.75 TDO2 (0.55) MAPK1TP53TDO2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 MAPK1 1754/4885TP53 855/4885FYN 2739/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 MAPK1 1969/4885TP53 947/4885FYN 2896/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 MAPK1 1639/4885TP53 890/4885FYN 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.